Literature DB >> 26224156

TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Keith A Josephs1, Jennifer L Whitwell2, Nirubol Tosakulwong3, Stephen D Weigand3, Melissa E Murray4, Amanda M Liesinger4, Leonard Petrucelli5, Matthew L Senjem2,6, Robert J Ivnik7, Joseph E Parisi8, Ronald C Petersen1, Dennis W Dickson4.   

Abstract

OBJECTIVE: The aim of this study was to determine whether the frequency of TAR DNA-binding protein 43 (TDP-43) deposition in Alzheimer's disease (AD) differs across pathologically defined AD subtypes (hippocampal sparing [HpSp]; typical and limbic) and further examine the relationship between TDP-43, pathological subtype, and clinical features in AD.
METHODS: We identified all cases with pathologically confirmed AD (NIA-Reagan intermediate-high probability, Braak stage IV-VI) independent of cognitive status (n = 188). Neurofibrillary tangle counts were performed using thioflavin-S microscopy in hippocampus and three neocortical regions, and all cases were subtyped: HpSp AD pathology (n = 19); typical AD pathology (n = 136); and limbic AD pathology (n = 33). TDP-43 immunoreactivity was performed in multiple brain regions to assess for the presence of TDP-43 and TDP-43 stage. All cases were clinically subclassified at presentation as amnestic AD dementia versus atypical AD dementia. Statistical analysis was performed using linear and penalized logistic regression to assess associations with pathological subtype, and the effects of TDP-43, accounting for possible interactions between pathological subtype and TDP-43.
RESULTS: TDP-43 deposition was frequent in typical (59%) and limbic AD pathologies (67%), but not HpSp AD pathology (21%; p = 0.003). The observed associations of TDP-43 with greater memory loss, naming and functional decline, and smaller hippocampal volumes, closest to death, did not differ across AD pathological subtype. Clinical presentation was associated with pathological subtype (p = 0.01), but not TDP-43 (p = 0.69).
INTERPRETATION: Although the frequency of TDP-43 deposition in AD varies by pathological subtype, the observed effects of TDP-43 on clinical/magnetic resonance imaging features are consistent across pathological subtypes. Clinical presentation in AD is driven by pathological subtype, not by TDP-43.
© 2015 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26224156      PMCID: PMC4623932          DOI: 10.1002/ana.24493

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

2.  Unlocking the mysteries of TDP-43.

Authors:  Keith A Josephs; Peter T Nelson
Journal:  Neurology       Date:  2015-02-04       Impact factor: 9.910

3.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Harald Hampel; José Luis Molinuevo; Kaj Blennow; Steven T DeKosky; Serge Gauthier; Dennis Selkoe; Randall Bateman; Stefano Cappa; Sebastian Crutch; Sebastiaan Engelborghs; Giovanni B Frisoni; Nick C Fox; Douglas Galasko; Marie-Odile Habert; Gregory A Jicha; Agneta Nordberg; Florence Pasquier; Gil Rabinovici; Philippe Robert; Christopher Rowe; Stephen Salloway; Marie Sarazin; Stéphane Epelbaum; Leonardo C de Souza; Bruno Vellas; Pieter J Visser; Lon Schneider; Yaakov Stern; Philip Scheltens; Jeffrey L Cummings
Journal:  Lancet Neurol       Date:  2014-06       Impact factor: 44.182

4.  TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism.

Authors:  Youngsin Jung; Dennis W Dickson; Melissa E Murray; Jennifer L Whitwell; David S Knopman; Bradley F Boeve; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Keith A Josephs
Journal:  J Neurol       Date:  2014-04-24       Impact factor: 4.849

5.  Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging.

Authors:  J L Whitwell; W R Crum; H C Watt; N C Fox
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

6.  Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.

Authors:  Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Ann Neurol       Date:  2015-04-22       Impact factor: 10.422

7.  Progressive aphasia secondary to Alzheimer disease vs FTLD pathology.

Authors:  K A Josephs; J L Whitwell; J R Duffy; W A Vanvoorst; E A Strand; W T Hu; B F Boeve; N R Graff-Radford; J E Parisi; D S Knopman; D W Dickson; C R Jack; R C Petersen
Journal:  Neurology       Date:  2008-01-01       Impact factor: 9.910

8.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.

Authors:  K A Josephs; J L Whitwell; D S Knopman; W T Hu; D A Stroh; M Baker; R Rademakers; B F Boeve; J E Parisi; G E Smith; R J Ivnik; R C Petersen; C R Jack; D W Dickson
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

9.  Differential clinicopathologic and genetic features of late-onset amnestic dementias.

Authors:  Melissa E Murray; Ashley Cannon; Neill R Graff-Radford; Amanda M Liesinger; Nicola J Rutherford; Owen A Ross; Ranjan Duara; Minerva M Carrasquillo; Rosa Rademakers; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-06-05       Impact factor: 17.088

10.  Staging TDP-43 pathology in Alzheimer's disease.

Authors:  Keith A Josephs; Melissa E Murray; Jennifer L Whitwell; Joseph E Parisi; Leonard Petrucelli; Clifford R Jack; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2013-11-16       Impact factor: 17.088

View more
  60 in total

1.  Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43.

Authors:  Mingkuan Sun; William Bell; Katherine D LaClair; Jonathan P Ling; Heather Han; Yusuke Kageyama; Olga Pletnikova; Juan C Troncoso; Philip C Wong; Liam L Chen
Journal:  Acta Neuropathol       Date:  2017-03-22       Impact factor: 17.088

2.  Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With Sclerosis.

Authors:  Matthew D Cykowski; Suzanne Z Powell; Paul E Schulz; Hidehiro Takei; Andreana L Rivera; Robert E Jackson; Gustavo Roman; Gregory A Jicha; Peter T Nelson
Journal:  Arch Pathol Lab Med       Date:  2017-05-03       Impact factor: 5.534

3.  Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases.

Authors:  Emmanuelle C Genin; Sylvie Bannwarth; Françoise Lespinasse; Bernardo Ortega-Vila; Konstantina Fragaki; Kie Itoh; Elodie Villa; Sandra Lacas-Gervais; Manu Jokela; Mari Auranen; Emil Ylikallio; Alessandra Mauri-Crouzet; Henna Tyynismaa; Anna Vihola; Gaelle Augé; Charlotte Cochaud; Hiromi Sesaki; Jean-Ehrland Ricci; Bjarne Udd; Cristofol Vives-Bauza; Véronique Paquis-Flucklinger
Journal:  Neurobiol Dis       Date:  2018-08-06       Impact factor: 5.996

4.  Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration.

Authors:  Alexandre Bejanin; Melissa E Murray; Peter Martin; Hugo Botha; Nirubol Tosakulwong; Christopher G Schwarz; Matthew L Senjem; Gael Chételat; Kejal Kantarci; Clifford R Jack; Bradley F Boeve; David S Knopman; Ronald C Petersen; Caterina Giannini; Joseph E Parisi; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs
Journal:  Brain       Date:  2019-11-01       Impact factor: 13.501

5.  Language and spatial dysfunction in Alzheimer disease with white matter thorn-shaped astrocytes.

Authors:  Elisa de Paula França Resende; Amber L Nolan; Cathrine Petersen; Alexander J Ehrenberg; Salvatore Spina; Isabel E Allen; Howard J Rosen; Joel Kramer; Bruce L Miller; William W Seeley; Maria Luiza Gorno-Tempini; Zachary Miller; Lea T Grinberg
Journal:  Neurology       Date:  2020-01-30       Impact factor: 9.910

6.  TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease.

Authors:  Marina Buciuc; Jennifer L Whitwell; Bradley F Boeve; Tanis J Ferman; Jonathan Graff-Radford; Rodolfo Savica; Kejal Kantarci; Julie A Fields; David S Knopman; Ronald C Petersen; Joseph E Parisi; Melissa E Murray; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2020-01-31       Impact factor: 4.849

7.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

8.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

9.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.